Revolution Medicines Inc. (42Z)
Munich
Closed
Aug 24, 2026
Day's Range
180.4052 wk Range
31.00Overview - 42Z - Revolution Medicines Inc.
Key Statistics
Valuation
Enterprise Value
-225.04M
P/E (Trailing)
‪-30.31‬
PEG Ratio
‪-0.22‬
Price / Book
‪14.59‬
EV / EBITDA
‪0.20‬
Profitability
Return on Assets
‪-48.04%‬
Return on Equity
‪-69.34%‬
Ownership
Shares Outstanding
214.24M
Price stats
50-Day Avg
‪163.12‬
200-Day Avg
‪110.93‬
Peers - 42Z - Revolution Medicines Inc.
Peer Comparison
Compared with companies in Biotechnology listed on Munich.
- 42ZMunichRevolution Medicines Inc.+82.90%52-week change-30.67P/E (Trailing)—Profit Margin
- 0QFMunichModerna, Inc.+82.56%52-week change25.19P/E (Trailing)‪-141.42%‬Profit Margin
- 4E2MunichRelmada Therapeutics Inc.+86.82%52-week change-2.80P/E (Trailing)—Profit Margin
- 5JA1MunichSprint Bioscience AB+82.07%52-week change0.28P/E (Trailing)‪92.17%‬Profit Margin
- B9B9P0MunichNovabay Pharmaceuticals Inc. R+80.00%52-week change-0.01P/E (Trailing)—Profit Margin
- 87EMunichDianthus Therapeutics Inc.+78.62%52-week change-22.50P/E (Trailing)—Profit Margin
- 5NRMunichNanobiotix S.A.+77.80%52-week change—P/E (Trailing)—Profit Margin
Profile Summary - 42Z - Revolution Medicines Inc.
About
Revolution Medicines Inc. is a clinical-stage precision oncology company focused on developing targeted cancer therapies. The company concentrates on inhibiting difficult-to-drug molecular targets within key cell growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways that are…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
